519 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Acquired by Weaver Consulting Group

Weaver Consulting Group acquired a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 519 shares of the biopharmaceutical company’s stock, valued at approximately $34,000.

Several other hedge funds and other institutional investors also recently modified their holdings of GILD. Vanguard Group Inc boosted its stake in shares of Gilead Sciences by 1.1% in the 3rd quarter. Vanguard Group Inc now owns 97,167,329 shares of the biopharmaceutical company’s stock worth $7,502,290,000 after buying an additional 1,071,619 shares during the last quarter. Advisors Asset Management Inc. boosted its stake in shares of Gilead Sciences by 45.5% in the 4th quarter. Advisors Asset Management Inc. now owns 91,175 shares of the biopharmaceutical company’s stock worth $5,703,000 after buying an additional 28,507 shares during the last quarter. Meridian Wealth Management LLC purchased a new position in shares of Gilead Sciences in the 4th quarter worth $459,000. ST Germain D J Co. Inc. boosted its stake in shares of Gilead Sciences by 18.4% in the 4th quarter. ST Germain D J Co. Inc. now owns 6,827 shares of the biopharmaceutical company’s stock worth $427,000 after buying an additional 1,060 shares during the last quarter. Finally, Meyer Handelman Co. boosted its stake in shares of Gilead Sciences by 9.4% in the 4th quarter. Meyer Handelman Co. now owns 314,450 shares of the biopharmaceutical company’s stock worth $19,669,000 after buying an additional 27,000 shares during the last quarter. 78.68% of the stock is owned by institutional investors.

In related news, Director John Francis Cogan sold 2,700 shares of Gilead Sciences stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $62.61, for a total value of $169,047.00. Following the completion of the transaction, the director now owns 57,560 shares in the company, valued at $3,603,831.60. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brett A. Pletcher sold 5,816 shares of Gilead Sciences stock in a transaction dated Tuesday, June 18th. The stock was sold at an average price of $68.75, for a total value of $399,850.00. Following the completion of the transaction, the executive vice president now owns 27,198 shares of the company’s stock, valued at approximately $1,869,862.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,084 shares of company stock valued at $928,423. 0.20% of the stock is currently owned by company insiders.

GILD has been the topic of a number of research reports. Maxim Group restated a “buy” rating and issued a $84.00 price target on shares of Gilead Sciences in a research note on Friday, March 29th. Citigroup upgraded Gilead Sciences from a “neutral” rating to a “buy” rating and set a $66.80 price target on the stock in a research note on Wednesday, May 22nd. Sanford C. Bernstein initiated coverage on Gilead Sciences in a report on Friday, April 26th. They issued an “outperform” rating and a $82.00 target price on the stock. UBS Group raised their target price on L Brands from $26.00 to $28.00 and gave the stock a “neutral” rating in a report on Wednesday, April 10th. Finally, Mizuho raised their target price on Iqvia from $145.00 to $150.00 and gave the stock a “neutral” rating in a report on Wednesday, June 19th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and fifteen have issued a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $79.54.

NASDAQ:GILD traded up $0.07 on Friday, reaching $66.26. 4,740,661 shares of the company’s stock traded hands, compared to its average volume of 6,160,793. The company has a debt-to-equity ratio of 1.09, a quick ratio of 3.53 and a current ratio of 3.62. The stock’s 50-day moving average is $66.66. The stock has a market capitalization of $84.47 billion, a price-to-earnings ratio of 10.77, a PEG ratio of 3.09 and a beta of 1.12. Gilead Sciences, Inc. has a 12 month low of $60.32 and a 12 month high of $79.61.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, beating the Zacks’ consensus estimate of $1.53 by $0.23. The business had revenue of $5.28 billion for the quarter, compared to analysts’ expectations of $5.29 billion. Gilead Sciences had a return on equity of 37.98% and a net margin of 26.40%. The business’s quarterly revenue was up 3.8% on a year-over-year basis. During the same period last year, the firm earned $1.48 earnings per share. As a group, sell-side analysts expect that Gilead Sciences, Inc. will post 6.6 EPS for the current year.

The business also recently declared a quarterly dividend, which was paid on Thursday, June 27th. Investors of record on Friday, June 14th were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, June 13th. This represents a $2.52 annualized dividend and a yield of 3.80%. Gilead Sciences’s dividend payout ratio is currently 40.98%.

About Gilead Sciences

Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.

Further Reading: 52-Week High/Low Prices For Stock Selection

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.